Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Inhibrx Inc is a biotechnology business based in the US. Inhibrx Inc shares (INBX) are listed on the NASDAQ and all prices are listed in US Dollars. Inhibrx Inc employs 106 staff and has a trailing 12-month revenue of around $7 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $29.76 |
|---|---|
| 52-week range | $7.67 - $47.90 |
| 50-day moving average | $18.37 |
| 200-day moving average | $20.85 |
| Wall St. target price | $47.17 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.45 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $29.76 from 2022-10-04
| 1 week (2022-09-28) | 72.02% |
|---|---|
| 1 month (2022-09-02) | N/A |
| 3 months (2022-07-06) | 90.77% |
| 6 months (2022-04-06) | 24.36% |
| 1 year (2021-10-06) | 5.57% |
|---|---|
| 2 years (2020-10-06) | 70.54% |
| 3 years (2019-10-02) | N/A |
| 5 years (2017-10-02) | N/A |
| Revenue TTM | $7 million |
|---|---|
| Gross profit TTM | $-64,209,000 |
| Return on assets TTM | -37.98% |
| Return on equity TTM | -562.25% |
| Profit margin | 0% |
| Book value | $0.70 |
| Market capitalisation | $771.4 million |
TTM: trailing 12 months
We're not expecting Inhibrx Inc to pay a dividend over the next 12 months.
Over the last 12 months, Inhibrx Inc's shares have ranged in value from as little as $7.67 up to $47.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inhibrx Inc's is 3.1144. This would suggest that Inhibrx Inc's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Inhibrx, Inc. , a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California. .
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.